Sensei Biotherapeutics (SNSE)
NASDAQ:SNSE
Want to see SNSE full AI Analyst Report?
Top Page
Sensei Biotherapeutics
(NASDAQ:SNSE)
Select Model
Select Model
Rating:46Neutral
Price Target:
$26.00
▲(127.67% Upside)
Action:ReiteratedDate:03/31/26
The score is held down primarily by weak financial performance (no revenue, ongoing losses and cash burn, and a shrinking equity/asset base despite modest leverage). Technicals are mixed but somewhat supportive longer-term, while valuation remains challenging due to negative earnings. Corporate events provide some offset via added capital and pipeline expansion, tempered by meaningful dilution and control structure changes.
Positive Factors
Pipeline expansion & financing
The Faeth acquisition added lead asset PIKTOR and the concurrent ~$200M Series B provides multi-quarter funding to advance Phase 2/1b programs. Structurally, this raises the probability of progressing clinical milestones and reduces immediate financing pressure for R&D execution over the next 2–6 months.
Negative Factors
Pre-revenue profile
Sensei remains wholly dependent on external capital because it reports no commercial revenue across multiple years. That dependency is structural for clinical-stage biotech and means future operating continuity and milestone execution hinge on successful fundraising or partnerships, raising long-term dilution and execution risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Pipeline expansion & financing
The Faeth acquisition added lead asset PIKTOR and the concurrent ~$200M Series B provides multi-quarter funding to advance Phase 2/1b programs. Structurally, this raises the probability of progressing clinical milestones and reduces immediate financing pressure for R&D execution over the next 2–6 months.
Read all positive factors
Sensei Biotherapeutics (SNSE) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$36.16M
Dividend YieldN/A
Average Volume (3M)38.93K
Price to Earnings (P/E)―
Beta (1Y)1.62
Revenue GrowthN/A
EPS Growth19.36%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-16.72
Shares Outstanding1,341,140
10 Day Avg. Volume109,584
30 Day Avg. Volume38,927
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.72
Price to Sales (P/S)0.00
P/FCF Ratio-0.66
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue-5.91
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.37
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-15.05
Revenue Forecast (FY)N/A
Sensei Biotherapeutics Business Overview & Revenue Model
Company Description
Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is ...
How the Company Makes Money
Sensei Biotherapeutics does not have publicly disclosed, recurring revenue from commercial product sales because its programs are in clinical development rather than marketed. As a result, to the extent revenue is reported, it would generally be e...
Sensei Biotherapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
48
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | -551.00K | -571.00K | -1.81M | -685.00K |
| EBITDA | -20.91M | -29.52M | -33.39M | -46.56M | -35.44M |
| Net Income | -21.09M | -30.16M | -34.10M | -48.59M | -36.79M |
Balance Sheet | |||||
| Total Assets | 22.90M | 45.36M | 74.37M | 118.38M | 153.22M |
| Cash, Cash Equivalents and Short-Term Investments | 21.18M | 41.34M | 65.76M | 107.12M | 147.62M |
| Total Debt | 1.51M | 3.85M | 6.21M | 8.03M | 2.35M |
| Total Liabilities | 4.31M | 6.97M | 9.48M | 14.97M | 6.71M |
| Stockholders Equity | 18.59M | 38.39M | 64.89M | 103.41M | 146.51M |
Cash Flow | |||||
| Free Cash Flow | -20.47M | -24.82M | -32.20M | -39.35M | -32.28M |
| Operating Cash Flow | -20.45M | -24.67M | -32.02M | -39.03M | -30.26M |
| Investing Cash Flow | 19.77M | 22.44M | 38.41M | 49.95M | -143.12M |
| Financing Cash Flow | -645.00K | -787.00K | -11.17M | -287.00K | 163.94M |
Sensei Biotherapeutics Technical Analysis
Positive
11.42
Price Trends
26.99
Positive
18.27
Positive
13.64
Positive
Market Momentum
0.64
Positive
52.95
Neutral
41.38
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNSE, the sentiment is Positive. The current price of 11.42 is below the 20-day moving average (MA) of 30.21, below the 50-day MA of 26.99, and below the 200-day MA of 13.64, indicating a bullish trend. The MACD of 0.64 indicates Positive momentum. The RSI at 52.95 is Neutral, neither overbought nor oversold. The STOCH value of 41.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SNSE.
Sensei Biotherapeutics Risk Analysis
Sensei Biotherapeutics disclosed 67 risk factors in its most recent earnings report. Sensei Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Sensei Biotherapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $19.02M | -1.25 | -94.94% | ― | ― | 54.05% | |
47 Neutral | $9.72M | -0.31 | -97.58% | ― | 0.07% | 46.20% | |
46 Neutral | $36.16M | -0.71 | -83.59% | ― | ― | 19.36% | |
43 Neutral | $11.41M | -0.59 | -248.91% | ― | ― | 74.61% | |
42 Neutral | $5.94M | -0.75 | -420.31% | ― | -10.30% | -36.45% |
* Healthcare Sector Average
SNSE
Sensei Biotherapeutics
26.70
18.31
218.16%
CLRB
Cellectar Biosciences
2.83
-5.15
-64.54%
COCP
Cocrystal Pharma
1.31
-0.20
-13.25%
BRTX
BioRestorative Therapies
0.24
-1.64
-87.13%
BOLT
Bolt Biotherapeutics
5.06
-1.86
-26.88%
Sensei Biotherapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and ComplianceShareholder Meetings
Sensei Biotherapeutics Announces Leadership and Board Transitions
Neutral
Apr 16, 2026
On April 10, 2026, Sensei Biotherapeutics disclosed that three directors tendered conditional resignations effective two business days after the June 10, 2026 annual meeting, contingent on stockholder approval of proposals that would permit conver...
Business Operations and StrategyExecutive/Board ChangesM&A TransactionsPrivate Placements and FinancingRegulatory Filings and Compliance
Sensei Biotherapeutics Closes Faeth Acquisition and Financing
Positive
Feb 18, 2026
On February 17, 2026, Sensei Biotherapeutics completed a stock-for-stock acquisition of Faeth Therapeutics, making Faeth a wholly owned subsidiary and adding its lead asset PIKTOR to Sensei’s oncology pipeline. The deal significantly reshape...
Business Operations and StrategyExecutive/Board Changes
Sensei Biotherapeutics Expands Board, Adds Finance Expertise
Positive
Feb 13, 2026
On February 13, 2026, Sensei Biotherapeutics, Inc. expanded its board of directors from three to five members and appointed its President, Principal Executive Officer and General Counsel, Christopher W. Gerry, along with seasoned biopharma finance...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.